Found 43 clinical trials
A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with MTX in participants with moderately to severely active RA who have an inadequate response to MTX.
A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with MTX in participants with moderately to severely active RA who have an inadequate response to MTX.
- 55 views
- 23 Nov, 2020
- 1 location
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, …
- 103 views
- 24 Jan, 2021
- 27 locations
Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII
This is a multi-center, open-labeled, non-randomized, single arm investigator-initiated trial to evaluate the safety and efficacy of GEN0101 and Pembrolizmub combination in patients with advanced melanoma.
- 0 views
- 22 Jan, 2021
- 7 locations
Phase I Study of MOv18 IgE a First in Class Chimeric IgE Antibody in Patients With Advanced Solid Tumours
This first in human study of the new therapeutic antibody MOv18 IgE in patients with advanced cancer seeks to demonstrate the potential for the use of this IgE antibody as an example of the use of the IgE class of antibodies for the treatment of cancer.
- 167 views
- 27 Jan, 2021
- 4 locations
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies
In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with greater asthma control
- 22 views
- 28 Jan, 2021
- 1 location
NISCI - Nogo Inhibition in Spinal Cord Injury
The purpose of the NISCI trial is to test if an antibody therapy can improve movement and quality of life of tetraplegic patients. A previous trial showed this treatment is safe and well
- 19 views
- 02 May, 2021
- 32 locations
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
. Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. Giving blinatumomab and combination chemotherapy may work better than combination chemotherapy alone in treating patients
- 84 views
- 14 Jun, 2021
- 119 locations
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different …
- 1047 views
- 13 Jun, 2021
- 581 locations
A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of convalescent plasma under the …
- 69 views
- 24 Jan, 2021
- 3 locations
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
This is a phase II, double-blind, randomised, controlled, multicentre trial of topical HDIT101 versus placebo. HSV-1-positive patients with at least 6 orolabial herpes lesions in the last 12 months can be included. The patients need to present with 3 herpes lesions within a 9 months observation phase. With the occurrence …
- 30 views
- 27 Jan, 2021
- 5 locations